Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome
K Nakai(Kansai Medical University), Shingo Kato(Tokai University), Y Kodera(Aichi Medical University), Yoshiko Atsuta(Aichi Medical University), Satoshi Takahashi(Waseda University), Nobuyuki Hamajima(Nagoya University), Yoshinobu Kanda(Jichi Medical University), Ryuji Tanosaki(National Cancer Center), M Kasai(Sapporo Hokuyu Hospital), T Matsushima(Gunma University), S Fukuhara(Kansai Medical University), Hisashi Sakamaki(Tokyo Metropolitan Komagome Hospital), Shinichiro Okamoto(Keio University)
Cited by 119
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
|New England Journal of Medicine|2004|839
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
|Science Translational Medicine|2009|434